Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
8.48 USD +2.29% Intraday chart for Oncternal Therapeutics, Inc. -0.82% -20.93%
Apr. 18 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
Apr. 15 HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
AQ
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
AQ
Oncternal Therapeutics: Q4 Earnings Snapshot
AQ
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
AQ
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
AQ
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
AQ
Oncternal Therapeutics Announces Reverse Stock Split
AQ
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)
AQ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
AQ
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
AQ
Oncternal Therapeutics: Q3 Earnings Snapshot
AQ
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
AQ
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
AQ
Penny Stock Momentum Watchlist (SING, CDIX, PXMD, ONCT)
AQ
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
AQ
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
AQ
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
AQ
Oncternal Therapeutics : Corporate Presentation, October 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCT Stock
  4. News Oncternal Therapeutics, Inc.
  5. Press Releases